EGFR and non-small cell lung carcinoma: Our study indicates that bispecific antibody-based regimens demonstrate superior PFS and ORR compared with chemo or ICI-chemo, both at the study level and the patient level, in patients with EGFR-mutated advanced NSCLC who have progressed after TKI treatment.